Why Did SoFi Stock Drop?
Fintech platform SoFi (NASDAQ:SOFI) has stumbled in recent days, selling…
Buy
72
DSGN Quote, Financials, Valuation and Earnings
Last price:
$9.82
Seasonality move
:
-15.75%
Day range:
$9.69 - $10.31
52-week range:
$2.60 - $10.31
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
2.79x
Volume:
296.6K
Avg. volume:
401.6K
1-year change:
58.09%
Market cap:
$556.5M
Revenue:
--
EPS (TTM):
-$1.19
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
DSGN
Design Therapeutics, Inc.
|
-- | -$0.34 | -- | -34.27% | $13.50 |
|
BRKR
Bruker Corp.
|
$847M | $0.33 | -2.12% | 622.18% | $48.83 |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$3M | -$0.88 | 14.03% | -95.43% | $0.85 |
|
PTN
Palatin Technologies
|
-- | -$0.17 | -- | -67.93% | -- |
|
RCEL
AVITA Medical, Inc.
|
$19.5M | -$0.29 | -5.31% | -22.01% | $7.92 |
|
TOVX
Theriva Biologics, Inc.
|
-- | -$0.21 | -- | -94.42% | $7.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
DSGN
Design Therapeutics, Inc.
|
$9.77 | $13.50 | $556.5M | -- | $0.00 | 0% | -- |
|
BRKR
Bruker Corp.
|
$48.03 | $48.83 | $7.3B | 77.08x | $0.05 | 0.42% | 2.12x |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$1.21 | $0.85 | $152.5M | 2.03x | $0.80 | 0% | 2.35x |
|
PTN
Palatin Technologies
|
$0.09 | -- | $2.4M | -- | $0.00 | 0% | -- |
|
RCEL
AVITA Medical, Inc.
|
$3.50 | $7.92 | $106.7M | -- | $0.00 | 0% | 1.30x |
|
TOVX
Theriva Biologics, Inc.
|
$0.23 | $7.00 | $7.6M | -- | $0.00 | 0% | 0.33x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
DSGN
Design Therapeutics, Inc.
|
0.87% | -0.176 | 0.41% | 18.43x |
|
BRKR
Bruker Corp.
|
45.23% | 0.852 | 40.19% | 0.76x |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
37.25% | 2.113 | 8.08% | 1.85x |
|
PTN
Palatin Technologies
|
-- | 1.358 | -- | -- |
|
RCEL
AVITA Medical, Inc.
|
117.49% | -1.939 | 28.73% | 0.52x |
|
TOVX
Theriva Biologics, Inc.
|
29.07% | -3.365 | 66.16% | 0.68x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
DSGN
Design Therapeutics, Inc.
|
-$155K | -$19.3M | -29.43% | -29.71% | -- | -$11.2M |
|
BRKR
Bruker Corp.
|
$399.6M | $55.2M | -0.56% | -1.2% | 6.42% | -$54.1M |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$42K | -$1.2M | -208.55% | -306.03% | -224.38% | -$1.8M |
|
PTN
Palatin Technologies
|
-- | -- | -- | -- | -- | -- |
|
RCEL
AVITA Medical, Inc.
|
$13.9M | -$9.2M | -111.55% | -1112.54% | -53.65% | -$6.5M |
|
TOVX
Theriva Biologics, Inc.
|
-$28K | -$4.4M | -148.18% | -171.04% | -- | -$4.3M |
Design Therapeutics, Inc. vs. Competitors
-
Which has Higher Returns DSGN or BRKR?
Bruker Corp. has a net margin of -- compared to Design Therapeutics, Inc.'s net margin of -6.8%. Design Therapeutics, Inc.'s return on equity of -29.71% beat Bruker Corp.'s return on equity of -1.2%.
Company Gross Margin Earnings Per Share Invested Capital DSGNDesign Therapeutics, Inc.-- -$0.30 $201.5M BRKRBruker Corp.46.44% -$0.41 $4.5B -
What do Analysts Say About DSGN or BRKR?
Design Therapeutics, Inc. has a consensus price target of $13.50, signalling upside risk potential of 38.18%. On the other hand Bruker Corp. has an analysts' consensus of $48.83 which suggests that it could grow by 1.67%. Given that Design Therapeutics, Inc. has higher upside potential than Bruker Corp., analysts believe Design Therapeutics, Inc. is more attractive than Bruker Corp..
Company Buy Ratings Hold Ratings Sell Ratings DSGNDesign Therapeutics, Inc.2 0 0 BRKRBruker Corp.5 6 0 -
Is DSGN or BRKR More Risky?
Design Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Bruker Corp. has a beta of 1.174, suggesting its more volatile than the S&P 500 by 17.405%.
-
Which is a Better Dividend Stock DSGN or BRKR?
Design Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Bruker Corp. offers a yield of 0.42% to investors and pays a quarterly dividend of $0.05 per share. Design Therapeutics, Inc. pays -- of its earnings as a dividend. Bruker Corp. pays out 26.44% of its earnings as a dividend. Bruker Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios DSGN or BRKR?
Design Therapeutics, Inc. quarterly revenues are --, which are smaller than Bruker Corp. quarterly revenues of $860.5M. Design Therapeutics, Inc.'s net income of -$17M is higher than Bruker Corp.'s net income of -$58.5M. Notably, Design Therapeutics, Inc.'s price-to-earnings ratio is -- while Bruker Corp.'s PE ratio is 77.08x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Design Therapeutics, Inc. is -- versus 2.12x for Bruker Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income DSGNDesign Therapeutics, Inc.-- -- -- -$17M BRKRBruker Corp.2.12x 77.08x $860.5M -$58.5M
-
Which has Higher Returns DSGN or NBY?
NovaBay Pharmaceuticals, Inc. has a net margin of -- compared to Design Therapeutics, Inc.'s net margin of -255.85%. Design Therapeutics, Inc.'s return on equity of -29.71% beat NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03%.
Company Gross Margin Earnings Per Share Invested Capital DSGNDesign Therapeutics, Inc.-- -$0.30 $201.5M NBYNovaBay Pharmaceuticals, Inc.8.06% -$0.22 $2.6M -
What do Analysts Say About DSGN or NBY?
Design Therapeutics, Inc. has a consensus price target of $13.50, signalling upside risk potential of 38.18%. On the other hand NovaBay Pharmaceuticals, Inc. has an analysts' consensus of $0.85 which suggests that it could fall by -29.75%. Given that Design Therapeutics, Inc. has higher upside potential than NovaBay Pharmaceuticals, Inc., analysts believe Design Therapeutics, Inc. is more attractive than NovaBay Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings DSGNDesign Therapeutics, Inc.2 0 0 NBYNovaBay Pharmaceuticals, Inc.1 0 0 -
Is DSGN or NBY More Risky?
Design Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals, Inc. has a beta of 0.569, suggesting its less volatile than the S&P 500 by 43.103%.
-
Which is a Better Dividend Stock DSGN or NBY?
Design Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.80 per share. Design Therapeutics, Inc. pays -- of its earnings as a dividend. NovaBay Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios DSGN or NBY?
Design Therapeutics, Inc. quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals, Inc. quarterly revenues of $521K. Design Therapeutics, Inc.'s net income of -$17M is lower than NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M. Notably, Design Therapeutics, Inc.'s price-to-earnings ratio is -- while NovaBay Pharmaceuticals, Inc.'s PE ratio is 2.03x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Design Therapeutics, Inc. is -- versus 2.35x for NovaBay Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income DSGNDesign Therapeutics, Inc.-- -- -- -$17M NBYNovaBay Pharmaceuticals, Inc.2.35x 2.03x $521K -$1.3M
-
Which has Higher Returns DSGN or PTN?
Palatin Technologies has a net margin of -- compared to Design Therapeutics, Inc.'s net margin of --. Design Therapeutics, Inc.'s return on equity of -29.71% beat Palatin Technologies's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital DSGNDesign Therapeutics, Inc.-- -$0.30 $201.5M PTNPalatin Technologies-- -- -- -
What do Analysts Say About DSGN or PTN?
Design Therapeutics, Inc. has a consensus price target of $13.50, signalling upside risk potential of 38.18%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 7338.9%. Given that Palatin Technologies has higher upside potential than Design Therapeutics, Inc., analysts believe Palatin Technologies is more attractive than Design Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings DSGNDesign Therapeutics, Inc.2 0 0 PTNPalatin Technologies0 0 0 -
Is DSGN or PTN More Risky?
Design Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.939, suggesting its less volatile than the S&P 500 by 6.103%.
-
Which is a Better Dividend Stock DSGN or PTN?
Design Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Design Therapeutics, Inc. pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios DSGN or PTN?
Design Therapeutics, Inc. quarterly revenues are --, which are larger than Palatin Technologies quarterly revenues of --. Design Therapeutics, Inc.'s net income of -$17M is higher than Palatin Technologies's net income of --. Notably, Design Therapeutics, Inc.'s price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Design Therapeutics, Inc. is -- versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income DSGNDesign Therapeutics, Inc.-- -- -- -$17M PTNPalatin Technologies-- -- -- --
-
Which has Higher Returns DSGN or RCEL?
AVITA Medical, Inc. has a net margin of -- compared to Design Therapeutics, Inc.'s net margin of -77.29%. Design Therapeutics, Inc.'s return on equity of -29.71% beat AVITA Medical, Inc.'s return on equity of -1112.54%.
Company Gross Margin Earnings Per Share Invested Capital DSGNDesign Therapeutics, Inc.-- -$0.30 $201.5M RCELAVITA Medical, Inc.81.32% -$0.46 $38.1M -
What do Analysts Say About DSGN or RCEL?
Design Therapeutics, Inc. has a consensus price target of $13.50, signalling upside risk potential of 38.18%. On the other hand AVITA Medical, Inc. has an analysts' consensus of $7.92 which suggests that it could grow by 125.29%. Given that AVITA Medical, Inc. has higher upside potential than Design Therapeutics, Inc., analysts believe AVITA Medical, Inc. is more attractive than Design Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings DSGNDesign Therapeutics, Inc.2 0 0 RCELAVITA Medical, Inc.3 2 1 -
Is DSGN or RCEL More Risky?
Design Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison AVITA Medical, Inc. has a beta of 1.658, suggesting its more volatile than the S&P 500 by 65.807%.
-
Which is a Better Dividend Stock DSGN or RCEL?
Design Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. AVITA Medical, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Design Therapeutics, Inc. pays -- of its earnings as a dividend. AVITA Medical, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios DSGN or RCEL?
Design Therapeutics, Inc. quarterly revenues are --, which are smaller than AVITA Medical, Inc. quarterly revenues of $17.1M. Design Therapeutics, Inc.'s net income of -$17M is lower than AVITA Medical, Inc.'s net income of -$13.2M. Notably, Design Therapeutics, Inc.'s price-to-earnings ratio is -- while AVITA Medical, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Design Therapeutics, Inc. is -- versus 1.30x for AVITA Medical, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income DSGNDesign Therapeutics, Inc.-- -- -- -$17M RCELAVITA Medical, Inc.1.30x -- $17.1M -$13.2M
-
Which has Higher Returns DSGN or TOVX?
Theriva Biologics, Inc. has a net margin of -- compared to Design Therapeutics, Inc.'s net margin of --. Design Therapeutics, Inc.'s return on equity of -29.71% beat Theriva Biologics, Inc.'s return on equity of -171.04%.
Company Gross Margin Earnings Per Share Invested Capital DSGNDesign Therapeutics, Inc.-- -$0.30 $201.5M TOVXTheriva Biologics, Inc.-- -$0.45 $9.5M -
What do Analysts Say About DSGN or TOVX?
Design Therapeutics, Inc. has a consensus price target of $13.50, signalling upside risk potential of 38.18%. On the other hand Theriva Biologics, Inc. has an analysts' consensus of $7.00 which suggests that it could grow by 3004.21%. Given that Theriva Biologics, Inc. has higher upside potential than Design Therapeutics, Inc., analysts believe Theriva Biologics, Inc. is more attractive than Design Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings DSGNDesign Therapeutics, Inc.2 0 0 TOVXTheriva Biologics, Inc.1 1 0 -
Is DSGN or TOVX More Risky?
Design Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Theriva Biologics, Inc. has a beta of 0.342, suggesting its less volatile than the S&P 500 by 65.818%.
-
Which is a Better Dividend Stock DSGN or TOVX?
Design Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Design Therapeutics, Inc. pays -- of its earnings as a dividend. Theriva Biologics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios DSGN or TOVX?
Design Therapeutics, Inc. quarterly revenues are --, which are smaller than Theriva Biologics, Inc. quarterly revenues of --. Design Therapeutics, Inc.'s net income of -$17M is lower than Theriva Biologics, Inc.'s net income of -$4.4M. Notably, Design Therapeutics, Inc.'s price-to-earnings ratio is -- while Theriva Biologics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Design Therapeutics, Inc. is -- versus 0.33x for Theriva Biologics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income DSGNDesign Therapeutics, Inc.-- -- -- -$17M TOVXTheriva Biologics, Inc.0.33x -- -- -$4.4M
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Robinhood Win AI Investing?
Recently, online brokerage Robinhood (NASDAQ:HOOD) has been focused on introducing…
Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Buy
56
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
81
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 40x
Alerts
Buy
56
SMX alert for Dec 6
SMX (Security Matters) Plc [SMX] is up 134.09% over the past day.
Buy
62
PRAX alert for Dec 6
Praxis Precision Medicines, Inc. [PRAX] is up 30.47% over the past day.
Sell
13
PSN alert for Dec 6
Parsons Corp. [PSN] is down 21.1% over the past day.
